[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

How to Hunt for Mega-Cap Value After the SpaceX IPO

Now that SpaceX (SPCX) is a public company, moving into the public arena, and the focus is squarely on that and upcoming glamour trades, I’m doing what I typically do. I’m looking elsewhere. I’ll catch y’all after some of the space stocks blow up.

I’ve shifted to the top 20 U.S. mega-caps to hunt for value under the hood. At least on a trading basis, since so much of the market now reacts at speeds we investing veterans of the last century can’t easily rationalize. 

Fundamentals

See More
  • Market Capitalization, $K 549,784,256
  • Shares Outstanding, K 2,407,217
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,115 M
  • EBITDA $ 30,618 M
  • 60-Month Beta 0.26
  • Price/Sales 5.99
  • Price/Cash Flow 16.59
  • Price/Book 6.94

Options Overview Details

View History
  • Implied Volatility 25.66% (+0.87%)
  • Historical Volatility 21.05%
  • IV Percentile 91%
  • IV Rank 75.77%
  • IV High 29.89% on 03/27/26
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 7) 5.33 (2.33%)
  • Put/Call Vol Ratio 0.59
  • Today's Volume 26,680
  • Volume Avg (30-Day) 27,230
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 397,189
  • Open Int (30-Day) 360,868
  • Expected Range 223.06 to 233.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.83
  • Number of Estimates 7
  • High Estimate $2.88
  • Low Estimate $2.69
  • Prior Year $2.77
  • Growth Rate Est. (year over year) +2.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
220.84 +3.42%
on 06/01/26
241.60 -5.47%
on 06/11/26
-0.53 (-0.23%)
since 05/18/26
3-Month
220.37 +3.64%
on 05/11/26
247.21 -7.61%
on 04/02/26
-8.89 (-3.75%)
since 03/18/26
52-Week
149.04 +53.24%
on 06/20/25
251.71 -9.26%
on 03/02/26
+77.66 (+51.52%)
since 06/18/25

Most Recent Stories

More News
How to Hunt for Mega-Cap Value After the SpaceX IPO

I'm not buying into SpaceX following the record-setting IPO. But I am looking for big value elsewhere. Here's how I start my search.

GOOG : 367.46 (+1.48%)
GOOGL : 368.03 (+1.17%)
SPCX : 185.00 (-3.56%)
$SPX : 7,500.58 (unch)
BRK.A : 733,609.75 (-0.50%)
JPM : 325.22 (-2.47%)
BRK.B : 489.46 (-0.37%)
JNJ : 228.39 (-2.48%)
TOPT : 33.27 (+1.28%)
$IUXX : 30,406.19 (unch)
AMZN : 244.39 (+2.90%)
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

HUM : 360.65 (-0.37%)
JNJ : 228.39 (-2.48%)
LLY : 1,098.57 (-1.21%)
DXCM : 72.47 (+1.74%)
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company’s U.S. Vision operations, enhance supply chain resilience,...

JNJ : 228.39 (-2.48%)
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

STOCKHOLM , June 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced results from the investigational Phase 3 MonumenTAL-3 study...

JNJ : 228.39 (-2.48%)
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Expanded U.S. availability paired with new patient lifestyle quiz encourages informed decision-making ahead of cataract surgery. ...

JNJ : 228.39 (-2.48%)
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

STOCKHOLM , June 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY ® (nipocalimab-aahu) produced a...

JNJ : 228.39 (-2.48%)
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results

Tango Therapeutics shares rallied on Monday after recording impressive results for its pancreatic cancer drug. Here’s how you should play TNGX stock at current levels.

IDYA : 31.23 (-0.10%)
JNJ : 228.39 (-2.48%)
INCY : 98.22 (-0.78%)
TNGX : 27.97 (-13.38%)
RHHBY : 49.7400 (-2.59%)
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers Acquisition adds a proprietary degrader antibody conjugate...

JNJ : 228.39 (-2.48%)
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

LONDON , June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index...

JNJ : 228.39 (-2.48%)
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

LONDON , June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new biomarker exploratory analyses from the Phase 2 DAHLIAS study evaluating nipocalimab in adults with moderate-to-severe...

JNJ : 228.39 (-2.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 236.71
2nd Resistance Point 234.73
1st Resistance Point 231.56
Last Price 228.39
1st Support Level 226.41
2nd Support Level 224.43
3rd Support Level 221.26

See More

52-Week High 251.71
Last Price 228.39
Fibonacci 61.8% 212.49
Fibonacci 50% 200.38
Fibonacci 38.2% 188.26
52-Week Low 149.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.